Growth hormone optimizationBody compositionSleep qualityRecoveryPostoperative ileusAnti-emetic effectsBone density
GH/IGF-1 axis stimulationBody composition (fat-free mass)Bone turnover and bone mineral densityAppetite stimulationSleep architectureSarcopenia / frailty / catabolic states (hip fracture, dietary restriction)
Typical dosing
200–300 mcg · 1-3x daily · 8-12 weeks
1x daily · Commonly cited as 8-12 week blocks with breaks; long-term continuous use carries metabolic risk
FDA status
Not FDA-approved. Not on the 503A bulks list and in none of FDA's interim Category 1, 2, or 3 lists — there is no lawful 503A or 503B compounding route.
Not FDA-approved; research-only. Ibutamoren mesylate is on FDA's interim Category 2 list — substances FDA has identified as raising significant safety risks and intends to act against in compounding. No lawful compounding route.
WADA status
Prohibited (S2 — peptide hormones, growth factors, and related substances)
Prohibited at all times (WADA S2 — growth hormone secretagogues/mimetics, S2.2)
